Dallas, Texas 02/13/2014 (FINANCIALSTRENDS) – Affymetrix, Inc. (NASDAQ:AFFX) the Santa Clara-based genetic analysis consumables and services provider has had mixed week thus far. Known for its life Sciences and bio technology reach as well, this is one stock which saw downgrade to sell at the beginning of the week, moving to hold by end of it.
Affymetrix, Inc. (NASDAQ:AFFX) saw a down ward turn, post the announcement of the poor performing last quarter. The bio technology company had failed to meet expectations and investors chose to sell.
However, there are analysts who view the current drop in the quarter as the potential for high returns in the near future.
Affymetrix, Inc. (NASDAQ:AFFX) proposed that it does hold higher value given the rich research and development the company is currently involved in. This has also meant that much of the investment for the company is in hidden costs of research and development.
Affymetrix, Inc. (NASDAQ:AFFX) which is also involved in the production of microarray-products which are used extensively by leading research communities across the world. The main line of scientific development for the company has been its DNA chip technology which allows gene expression. It is also involved in the analysis as well as clinical applications for treating different diseases. These include such condition as cancer or diseases caused by infection.
Affymetrix, Inc. (NASDAQ:AFFX) is currently seen as bullish by analysts such as Zacks. The premise is the positive Earnings, as well as revisions in estimations. The life sciences company has reported that it holds loads of promise due to sales which are in the region of 7.8%. The increase in the past year is seen as $84.4 million. The third quarter results had beat expectations by over $0.2 on a share.
Affymetrix Inc, with high focus on research and development is expected to see high value growth in the next quarters. This stock holds great promise based on the technology and continued development focus it holds!